A label change has been approved by the FDA for ferric carboxymaltose injection (Injectafer in the US but registered in South Africa as Ferinject and distributed by Aspen Pharmacare), warning of risk for symptomatic hypophosphatemia, reports MedPage Today.
In the boxed warning, the agency recommends monitoring of phosphate levels in patients at risk for hypophosphatemia and in any patient who receives a repeat course of therapy within three months of the prior course.
Ferric carboxymaltose is an iron replacement therapy that was originally approved in 2013. The intravenously delivered drug carries indications for treating iron deficiency anaemia in patients one year and older who cannot tolerate or don’t fully respond to oral iron; in adults who have non-dialysis-dependent chronic kidney disease; and in adults with heart failure and NYHA Association class II/III to improve exercise capacity.
The FDA had already made labelling changes for the injection in February 2020 and May 2023, adding and strengthening the warning about the risk of hypophosphatemia, respectively.
However, an assessment earlier this year found that symptomatic hypophosphatemia continues to be reported with ferric carboxymaltose injection.
An FDA Adverse Event Reporting System case series included reports of symptomatic hypophosphatemia that occurred after both single and multiple infusions of ferric carboxymaltose injection and resulted in hospitalisations, the need for phosphate replacement therapy over weeks to months, and extensive monitoring with regular follow-up medical visits.
Chronic hypophosphatemia associated with ferric carboxymaltose can also lead to osteomalacia (bone softening) and fractures, and the agency suggested that these serious adverse reactions can be prevented or reduced in severity through appropriate phosphate level monitoring and early intervention.
The FDA advised patients to report any new or worsening symptoms of low phosphate levels – which can include muscle weakness or pain, fatigue, bone and joint pain, tremors, confusion, or cardiac arrhythmias – to their healthcare providers.
In turn, providers should inform patients about the risk for hypophosphatemia with ferric carboxymaltose injection use. They should also correct pre-existing hypophosphatemia before administering the drug, treat hypophosphatemia as medically indicated, and consider permanent discontinuation of ferric carboxymaltose for severe symptomatic hypophosphatemia or persistent hypophosphatemia.
MedPage Today article – FDA adds boxed warning to iron replacement injection (Open access)
See more from MedicalBrief archives:
Iron supplement injection cuts heart failure re-hospitalisation by 26%
Malawi study explores injectable versus oral iron for anaemia in pregnancy